Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01729260 · ClinicalTrials.gov registry record · Phase 1
Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide
A Phase 1 study of Newly Diagnosed High-Grade Glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01729260: Completed Phase 1 study of Newly Diagnosed High-Grade Glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT01729260 is a Phase 1 study of Newly Diagnosed High-Grade Glioma that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01729260, a Phase 1 study of Newly Diagnosed High-Grade Glioma, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find the highest dose of mebendazole (MBZ) that can be safely given to people with malignant brain tumors in combination with the current standard of care (temozolomide) without causing severe side effects. We also want to find out if MBZ can slow the growth of the brain tumor. The study doctors have found that MBZ is effective against malignant brain tumors in the laboratory and animal models of brain tumors.
Primary Outcome
To determine the maximum tolerated dose (MTD) of mebendazole in combination with temozolomide (TMZ) given after surgery and the standard radiation and TMZ treatment in patients with newly diagnosed malignant gliomas.
Conditions Studied
Interventions
- DRUG Mebendazole
Study Locations (1)
Maryland
- The Johs Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-04-04 |
| Est. Completion | 2021-04-16 |
| Phase | Phase 1 |
What the finished NCT01729260 record still lists
NCT01729260 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Newly Diagnosed High-Grade Glioma appearing as the primary indexed condition, and to 1 intervention - of which Mebendazole is the first listed.
NCT01729260 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01729260 about?
NCT01729260 is a clinical study titled "Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide". The purpose of this study is to find the highest dose of mebendazole (MBZ) that can be safely given to people with malignant brain tumors in combination with the current standard of care (temozolomide) without causing severe side effects. We also want to find out if MBZ can slow the growth of the br...
What is the current status of trial NCT01729260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-04-04. Estimated completion is 2021-04-16.
What conditions does trial NCT01729260 study?
This clinical trial studies the following conditions: Newly Diagnosed High-Grade Glioma.
What interventions are being tested in trial NCT01729260?
The interventions under investigation include: Mebendazole (DRUG).
Who is sponsoring clinical trial NCT01729260?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01729260 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01729260's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI